Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.62 |
| ▸ | HTR3B | O95264 | 4/20 | 0.62 |
| ▸ | HTR3A | P46098 | 4/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 4/20 | 0.51 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15247189 | 0.93 | ADRB1 (0.55) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL20884025 | 0.89 | ADRB1 (0.48) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL20251137 | 0.85 | MAPT (0.51) | KDM4EALDH1A1LMNA | |
| SCHEMBL13344707 | 0.85 | ADRB1 (0.58) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL21384917 | 0.85 | ADRB1 (0.58) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL28295694 | 0.85 | ADRB1 (0.58) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL18012470 | 0.85 | ADRB1 (0.58) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL21731341 | 0.84 | L3MBTL3 (0.53) | ADRB1SIGMAR1HTR3EHTR3BHTR3A | |
| SCHEMBL5458305 | 0.83 | ALDH1A1 (0.57) | KDM4EALDH1A1LMNA | |
| SCHEMBL5570604 | 0.82 | ADRB1 (0.77) | ADRB1SIGMAR1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| CN-1145620-A | New piperazine derivatives and its prepn. | SAMJIN PHARM CO LTD (KR) | 1997-03-19 | — | — | CN | disclosed |
| EP-0749425-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARM. CO., LTD. (KR) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996021648-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1996-07-18 | — | — | WO | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ADRB1 1589/4885SIGMAR1 4592/4885HTR3E 836/4885 |
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | ADRB1 4505/4885SIGMAR1 3072/4885HTR3E 3475/4885 |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | ADRB1 495/4885SIGMAR1 544/4885HTR3E 518/4885 |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAK4, PAK2, PAK1 | ADRB1 3574/4885SIGMAR1 4826/4885HTR3E 3649/4885 |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | ADRB1 4789/4885SIGMAR1 4346/4885HTR3E 3880/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | ADRB1 3444/4885SIGMAR1 4065/4885HTR3E 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.